Research Article
LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn’s Disease
Table 2
Clinical characteristics of Crohn’s disease and healthy control.
| | Crohn’s disease | Healthy control | | Clinical active | Clinical remission | Endoscopic active | Endoscopic remission |
| | Number () | 90 | 78 | 48 | 30 | 65 | | Age (years, median (min, max)) | 35.9 (15-82) | 36.7 (15-78) | 36.5 (15-68) | 40.5 (25-60) | 30.9 (22-62) | | Gender (M/F) () | 44/46 | 41/37 | 25/23 | 18/12 | 35/30 | | Disease duration (months, median (min, max)) | 120(12-372) | 98(12-360) | 108(11-273) | 132(13-360) | | | Current therapy () | | | | | | | 5-Aminosalicylates | 44 | 54 | 26 | 20 | | | Immunosuppressants | 30 | 38 | 12 | 15 | | | Biologics | 68 | 61 | 37 | 22 | | | Nutritional therapy | 17 | 10 | 9 | 2 | | | Disease location | | | | | | | L1 | 43 | 20 | 22 | 10 | | | L2 | 22 | 16 | 11 | 6 | | | L3 | 25 | 42 | 15 | 14 | | | L4 | 0 | 0 | 0 | 0 | | | Disease behaviors | | | | | | | B1 | 44 | 28 | 25 | 13 | | | B2 | 33 | 38 | 16 | 12 | | | B3 | 13 | 12 | 7 | 5 | | | ESR (mm/h, median (min, max)) | 31.1 (7-110) | 8 (2-22) | 29 (2-110) | 9.25 (2-22) | NA | | CRP (mg/L, median (min, max)) | 44.5 (8.1-155.1) | 8.5 (0.23-31.1) | 33.7 (0.7-129) | 9.1 (0.2-30.7) | NA | | PLT ((×109/L, median (min, max)) | 286.5 (78.2-535) | 191.8 (112-392) | 271.7 (78.2-535) | 199.5 (112-331) | NA | | FC ((μg/g, median (min, max)) | 132.3 (39.8-323.2) | 32.3 (8.7-52.2) | 100.7 (10.7-323.2) | 33.4 (13.2-58.2) | NA | | CDAI (median (min, max)) | 223.5 (1533.5-424.2) | 69.0 (45.3-141.8) | 208.8 (54.8-424.2) | 71.2 (43.3-96.7) | NA |
|
|
CD: Crohn’s disease; CDAI: clinical disease activity index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; FC: fecal calprotectin; PLT: platelet; F: female; M: male; NA: not available; min: minimum; max: maximum; L1: ileal; L2: colonic; L3: ileocolonic; L4: upper; B1: nonstricturing, nonpenetrating; B2: stricturing; B3: penetrating.
|
